{"article_title": "Health Care ETFs", "article_keywords": ["index", "sp", "companies", "smallcap", "pharmaceuticals", "etfs", "growth", "health", "biotechnology", "stocks", "care"], "article_url": "http://www.etftrends.com/2013/09/three-etfs-to-play-up-and-coming-health-care-companies/", "article_text": "Rummaging through small-cap biotechnology companies, investors can pick out the next break-through drug provider, but it also leaves you exposed to potential flubs. Instead, exchange traded funds offer diversified basket to the growing sector.\n\n\u201cThe jarring pace of change, single-product liability, regulatory uncertainties, and intellectual property rights make picking stocks in the biotech sector a high-risk/high-reward proposition,\u201d according to Morningstar analyst Robert Goldsborough. \u201cAs such, we think investing in the industry via an exchange-traded fund makes a lot of sense; it\u2019s a low-cost way to gain diverse exposure to the industry in one trade.\u201d\n\nThe health care space could benefit from the aging population, rise in chronic diseases due to the older population, growing emerging market demand, new discoveries, increased merger and acquisitions activity, and the implementation of the Affordable Care Act, or \u201cObamacare,\u201d according to Zacks. [Three ETFs to Play the Outperforming Biotech Sector]\n\nLooking at small-capitalization health care stocks, these companies focus on domestic exposure. Since they don\u2019t have a large international footprint, they rely more on the U.S. economy, which could be a plus in case the world economy slows. [Tech and Healthcare ETFs: Are They All That We Have Left?]\n\nMoreover, smaller companies tend to experience faster growth, compared to their large-cap counterparts in an expanding economy. However, small-caps also see greater levels of volatility.\n\nThe PowerShares Dynamic Biotechnology & Genome Portfolio (NYSEArca: PBE) tries to reflect the performance of the Dynamic Biotechnology & Genome Intellidex Index, which tracks companies engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit from scientific and technological advances in biotechnology and genetic engineering and research. The fundamental index picks stocks based on price momentum, earnings momentum, quality, management action and value. PBE has a 0.63% expense ratio.\n\nThe fund holds 30 stocks. Top holdings include Gilead Sciences 5.0%, Illumina 4.9%, Amgen 4.8%, Waters Corp 4.5% and Regeneron Pharmaceuticals 4.5%.\n\nMarket-capitalization includes large-cap growth 18.2%, mid-cap growth 36.6%, small-cap growth 42.2% and small-cap value 3.1%.\n\nThe Biotech & Genome ETF is up 45.9% year-to-date.\n\nThe PowerShares S&P SmallCap Health Care Portfolio (NYSEArca: PSCH) tries to reflect the performance of the S&P SmallCap 600 Capped Health Care Index, which follows healthcare companies engaged in providing healthcare-related products and services, including biotechnology, pharmaceuticals, medical technology and supplies, and facilities. PSCH has a 0.29% expense ratio.\n\nThe fund has 65 components. Top holdings include Cubist Pharmaceuticals 6.1%, Questcor Pharmaceuticals 5.9%, Centene 4.6%, Align Technology 4.6% and Parexel International 3.9%.\n\nMarket-capitalization includes mid-cap growth 10.6%, small-cap growth 72.9% and small-cap value 16.5%.\n\nPSCH is up 33.9% year-to-date.\n\nThe SPDR S&P Biotech ETF (NYSEArca: XBI) tries to reflect the performance of the S&P Biotechnology Select Industry Index, which represents the biotech sector of the S&P Total Market Index. The underlying index also employs an equal-weight methodology. XBI has a 0.35% expense ratio.\n\nThe ETF holds 58 stocks. Top holdings include Alnyiam Pharmaceuticals 3.1%, NPS Pharmaceuticals 3.0%, Incyte Corp. 2.9%, InterMune 2.9% and Celldex Therapeutics 2.5%.\n\nMarket-capitalization includes giant-cap, 6.3%, large-cap 7.5%, mid-cap 26.1%, small-cap 36.5% and micro-cap 23.6%.\n\nXBI is up 37.5% year-to-date.\n\nFor more information on the health care sector, visit our health care category.\n\nMax Chen contributed to this article.\n\nThe opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.", "article_metadata": {"description": "Three small-cap health care ETFs.", "generator": "WordPress 4.5.2", "msapplication-TileImage": "http://www.etftrends.com/wp-content/uploads/2016/04/favicon-1.png", "keywords": "small-cap,etfs,etf,health care,biotechnology,biotech,pharmaceuticals,drugs,asset class etfs,pbe,psch,sector etfs,technology,xbi,featured", "google-site-verification": "Q-wAoS5rW2yMYxQN_OT0klqLjkfU6a6rxznKurdUlsY", "viewport": "width=device-width, initial-scale=1"}, "_id": "\"57477af46914bd0286fe2a2c\"", "article_summary": "For more information on the health care sector, visit our health care category.\n[Three ETFs to Play the Outperforming Biotech Sector]Looking at small-capitalization health care stocks, these companies focus on domestic exposure.\nThe PowerShares S&P SmallCap Health Care Portfolio (NYSEArca: PSCH) tries to reflect the performance of the S&P SmallCap 600 Capped Health Care Index, which follows healthcare companies engaged in providing healthcare-related products and services, including biotechnology, pharmaceuticals, medical technology and supplies, and facilities.\nMarket-capitalization includes large-cap growth 18.2%, mid-cap growth 36.6%, small-cap growth 42.2% and small-cap value 3.1%.\nRummaging through small-cap biotechnology companies, investors can pick out the next break-through drug provider, but it also leaves you exposed to potential flubs."}